Cancer and leukemia group B (CALGB) multidrug resistance modulation trials in untreated acute myeloid leukemia

被引：0
作者：
Kolitz, J. E.
George, S. L.
Baer, M. R.
Lee, E. J.
Bloomfield, C. D.
Larson, R. A.
机构：
[1] Canc & Leukemia Grp B, Chicago, IL USA
[2] N Shore Univ Hosp, Manhasset, NY USA
[3] Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ Chicago, Chicago, IL 60637 USA
来源：
ANNALS OF HEMATOLOGY | 2006年 / 85卷
关键词：
acute myeloid leukemia; MDR modulation; P-glycoprotein; PSC-833;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 11 条
[1]  
Baer MR, 2005, BLOOD, V106, p661A
[2]   Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 [J].
Baer, MR ;
George, SL ;
Dodge, RK ;
O'Loughlin, KL ;
Minderman, H ;
Caligiuri, MA ;
Anastasi, J ;
Powell, BL ;
Kolitz, JE ;
Schiffer, CA ;
Bloomfield, CD ;
Larson, RA .
BLOOD, 2002, 100 (04) :1224-1232
[3]  
Gerrard G, 2004, HAEMATOLOGICA, V89, P782
[4]   Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) [J].
Greenberg, PL ;
Lee, SJ ;
Advani, R ;
Tallman, MS ;
Sikic, BI ;
Letendre, L ;
Dugan, K ;
Lum, B ;
Chin, DL ;
Dewald, G ;
Paietta, E ;
Bennett, JM ;
Rowe, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1078-1086
[5]   Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of cancer and leukemia group B study 9621 [J].
Kolitz, JE ;
George, SL ;
Dodge, RK ;
Hurd, DD ;
Powell, BL ;
Allen, SL ;
Velez-Garcia, E ;
Moore, JO ;
Shea, TC ;
Hoke, E ;
Caligiuri, MA ;
Vardiman, JW ;
Bloomfield, CD ;
Larson, RA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4290-4301
[6]  
Kolitz JE, 2005, BLOOD, V106, p122A
[7]   Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of cancer and leukemia group B study 9420 [J].
Lee, EJ ;
George, SL ;
Caligiuri, M ;
Szatrowski, TP ;
Powell, BL ;
Lemke, S ;
Dodge, RK ;
Smith, R ;
Baer, M ;
Schiffer, CA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2831-2839
[8]  
LEGRAND O, 1995, LEUKEMIA, V9, P1025
[9]   Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study [J].
List, AF ;
Kopecky, KJ ;
Willman, CL ;
Head, DR ;
Persons, DL ;
Slovak, ML ;
Dorr, R ;
Karanes, C ;
Hynes, HE ;
Doroshow, JH ;
Shurafa, M ;
Appelbaum, FR .
BLOOD, 2001, 98 (12) :3212-3220
[10]   Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies [J].
Mahadevan, D ;
List, AF .
BLOOD, 2004, 104 (07) :1940-1951
12